Manara - Qatar Research Repository
Browse

Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review

Download (662.56 kB)
journal contribution
submitted on 2024-08-06, 11:50 and posted on 2024-08-06, 11:51 authored by Elise E. Dunning, Boris Decourt, Nasser H. Zawia, Holly A. Shill, Marwan N. Sabbagh

Progressive supranuclear palsy (PSP) is a neurodegenerative disorder resulting from the deposition of misfolded and neurotoxic forms of tau protein in specific areas of the midbrain, basal ganglia, and cortex. It is one of the most representative forms of tauopathy. PSP presents in several different phenotypic variations and is often accompanied by the development of concurrent neurodegenerative disorders. PSP is universally fatal, and effective disease-modifying therapies for PSP have not yet been identified. Several tau-targeting treatment modalities, including vaccines, monoclonal antibodies, and microtubule-stabilizing agents, have been investigated and have had no efficacy. The need to treat PSP and other tauopathies is critical, and many clinical trials investigating tau-targeted treatments are underway. In this review, the PubMed database was queried to collect information about preclinical and clinical research on PSP treatment. Additionally, the US National Library of Medicine’s ClinicalTrials.gov website was queried to identify past and ongoing clinical trials relevant to PSP treatment. This narrative review summarizes our findings regarding these reports, which include potential disease-modifying drug trials, modifiable risk factor management, and symptom treatments.

Other Information

Published in: Neurology and Therapy
License: https://creativecommons.org/licenses/by-nc/4.0
See article on publisher's website: https://dx.doi.org/10.1007/s40120-024-00614-9

Funding

National Institute on Aging (R01AG059008), MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients.

National Institute on Aging (R01AG073212), Repurposing Siponimod for Alzheimer's Disease.

National Institute on Aging (P30AG072980), Arizona Alzheimer's Disease Research Center.

History

Language

  • English

Publisher

Springer Nature

Publication Year

  • 2024

License statement

This Item is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License

Institution affiliated with

  • Hamad Bin Khalifa University
  • Qatar Biomedical Research Institute - HBKU